The Chemistry and Cancer Program (CCP) seeks to discover small molecule chemicals capable of either antagonizing or agonizing regulatory pathways relevant to human cancer. Research efforts in the CCP proceed from one of two directions, chemistry-to-biology or biology-to-chemistry. In the former case, the discovery process starts with a novel natural product that is cytotoxic to cancer cells. This molecule, and specific derivatives synthesized by organic chemists, is then subjected to biochemical, genetic or molecular biological studies aimed at resolving its precise mode of action. Alternatively, knowledge of a specific biological pathway relevant to human cancer prompts attempts to identify small chemical antagonists or agonists of the pathway. The latter path is prosecuted by high throughput drug screening, rational peptidomimetics, or preparation of synthetic analogs of biological metabolites. In this context, the current scientific program themes are: 1) Identifying the Molecular Targets of Novel Cytotoxic Agents. 2) Biochemical Dissection of Novel. Cancer Cell-Specific Pathways. 3 ) Smac mimetics and other means of perturbing apoptosis with synthetic chemicals. 4) Regulation and targeting of the hypoxia response pathway with small molecules. The long-term objective of the CCP is to discover """"""""first-in-class"""""""" chemical compounds, some of which may qualify for rigorous pre-clinical development. In doing so, we will provide the scientific expertise and resources from which program- and cancer center-wide translational research can sprout. Therefore, an additional major goal of the CCP is to develop and provide scientific and technical expertise in chemistry, pharmacology and High Throughput screening.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-04
Application #
8519956
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$42,147
Indirect Cost
$27,467
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mokdad, Ali A; Xie, Xian-Jin; Zhu, Hong et al. (2018) Statistical justification of expansion cohorts in phase 1 cancer trials. Cancer 124:3339-3345
Murphy, Caitlin C; Singal, Amit G; Baron, John A et al. (2018) Decrease in Incidence of Young-Onset Colorectal Cancer Before Recent Increase. Gastroenterology 155:1716-1719.e4
Barnes, Arti; Betts, Andrea C; Borton, Eric K et al. (2018) Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS 32:1861-1870
Murphy, Caitlin C; Fullington, Hannah M; Alvarez, Carlos A et al. (2018) Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer 124:2850-2857
Zhang, Shuyuan; Nguyen, Liem H; Zhou, Kejin et al. (2018) Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. Gastroenterology 154:1421-1434
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Chiang, Wei-Chung; Wei, Yongjie; Kuo, Yi-Chun et al. (2018) High-Throughput Screens To Identify Autophagy Inducers That Function by Disrupting Beclin 1/Bcl-2 Binding. ACS Chem Biol 13:2247-2260
Zhou, Heling; Arias-Ramos, Nuria; López-Larrubia, Pilar et al. (2018) Oxygenation Imaging by Nuclear Magnetic Resonance Methods. Methods Mol Biol 1718:297-313
Denman, Deanna C; Baldwin, Austin S; Betts, Andrea C et al. (2018) Reducing ""I Don't Know"" Responses and Missing Survey Data: Implications for Measurement. Med Decis Making 38:673-682
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435

Showing the most recent 10 out of 501 publications